71.00
+1.87%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Linc
Its shares trade on Nasdaq Stockholm under the ticker LINC.ST. It has been listed since 28 May 2021. In the fiscal year to 31 December 2025, it reported a net loss of SEK 399.6m. At that date it held total assets of SEK 4.44bn and shareholders' equity of SEK 4.43bn.
Linc AB is an investment company that focuses on long-term share ownership in the Nordic life science market. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-05-28. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The firm works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Financials
- Industry
- Capital Markets
- Listed since
- 28 May 2021
- Employees
- 2
- Website
- linc.se ↗
Leadership
Pay as last reported
- Mr. Bengt JulanderChairman of the Board, since 1991SEK 418,000
- Mr. Karl TobiesonChief Executive OfficerSEK 3.1m
- Mr. Thomas BerghChief Financial OfficerSEK 1.6m
- Ms. Marianne AlexanderssonIndependent DirectorSEK 223,000
- Ms. Ulrika DellbyIndependent DirectorSEK 207,000
- Mr. Anders HansenIndependent DirectorSEK 207,000
- Mr. Johan LanneboIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Linc AB focuses on long-term share ownership in Nordic life science market with 2 employees.
- Linc AB invests in both private and public companies within pharmaceutical and medical technology.
- Linc Invest actively supports portfolio companies with a wide industrial network.
Weaknesses
- Linc AB has only 2 full-time employees for a Nordic life science investment company.
- Linc AB's IPO was on 28 May 2021 with limited historical data.
- Linc AB's investments are primarily in drug development and medical technology phases.
Opportunities
- Linc AB can expand its portfolio in the Nordic life science market with growing pharmaceutical demand.
- Linc AB can leverage its industrial network to support more portfolio companies in medical technology.
- Linc AB can target private companies for investment in the Nordic life science sector.
Threats
- Linc AB faces competition from other Nordic investment firms in the life science market.
- Linc AB's small team size may limit its ability to manage a larger portfolio.
- Linc AB's focus on early-phase drug development could lead to higher investment risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.